SRTD Biotech
German biotech developing selectively expressed RNA for oncology, autoimmune disease and fibrosis.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Onodrim Industries, SRTD Biotech, T-Therapeutics — $300M for defence, €31.5M for RNA and $133M for bispecifics — Daily News November 9, 2026
Listen to the episodeAbout SRTD Biotech
SRTD Biotech is a biotech founded in 2019 in Jülich, Germany, by Chief Scientific Officer Bernd Hoffmann. It develops selectively expressed RNA (seRNA) constructs that switch on therapeutic mRNA only inside target cells by recognising their disease markers, together with lipid nanoparticles to reach organs such as the liver, lungs and brain and an RNA design platform based on bioinformatics and AI. On 9 November 2026 it closed an oversubscribed €31.5 million seed round led by Mérieux Equity Partners, co-led by NRW.BANK and Boehringer Ingelheim Venture Fund, with Lilly Ventures, HTGF and Anobis Asset; after the round it appointed Matthias Alder as CEO. The funds will take its still-preclinical pipeline to an Investigational New Drug filing.
The Story
Founded in Jülich in 2019 by biologist Bernd Hoffmann, now Chief Scientific Officer.
How SRTD Biotech works
Business Model
Development of proprietary drugs with possible licensing and partnership deals.
Products & Services
Key Products
- seRNA platform
- Fusogenic lipid nanoparticles
Core Use Cases
- RNA therapies for oncology
- RNA therapies for autoimmune disease
- RNA therapies for fibrosis
Market & Clients
Geographic Presence
How SRTD Biotech competes
Competitive Advantages
- RNA expression switched on only in target cells
How SRTD Biotech grows
Growth Strategy
Advance the preclinical pipeline to an IND filing.
Regulatory Context
Programmes must complete preclinical development and obtain clinical trial authorisation.
Key Risks
- Preclinical and clinical risk
- Insufficient selectivity or toxicity
- Long regulatory timelines
Strategic Insights
- The large seed round funds the move from platform to preclinical candidates.
- Corporate funds from Boehringer Ingelheim and Lilly open the door to future partnerships.
Funding & Investors
Funding Rounds
- 2026 - Seed: €31,5M
Lead: Mérieux Equity Partners
Key Investors
Founding Team
Founders
Key Executives
- Matthias Alder - CEO
Key Metrics
Lessons from SRTD Biotech
- In biotech, capital and industry investors do not replace repeatable data and safety evidence.
Similar Startups
HepaRegeniX
Innovative regenerative medicine solutions aimed at curing liver disease and improving patient outcomes.
Read AnalysisINVITRIS
Biotechnology company focused on advancing research and development in life sciences and medical technology.
Read AnalysisZedira
Specialised supplier of transglutaminase-related research products and services, catalysing academic and industrial R&D across food science, pharma, and biotech.
Read AnalysisSources
- Mérieux Innovation 2 invests in SRTD Biotech — Mérieux Equity Partners
- Jülich-based SRTD Biotech secures €31.5 million to develop precision mRNA therapies — EU-Startups